Ocata Therapeutics Report issue

For profit Phase 2
Founded: Marlborough MA United States (1994)
Status: Acquired by Astellas (2016) → now Leo Pharma (2015)

Organization Overview

First Clinical Trial
2013
NCT02122159
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2013

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 2 Trials (2)

Key: Ocata Therapeutics (1) Acquired (1)

autologous skeletal myoblast (1 trial)

ma09-hrpe (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Macular Degeneration (Phase 2)

Myopia (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2